Biotech and Money Ltd.

Biotech and Money Ltd.

Category: Content
Type: Blog Article

Generated 3 days ago

New blog articles detected

  • What you missed at Biotech and Money London 2017

    On the 7th and 8th February 2017, our 3rd annual conference continued our relentless focus on quality peer-2-peer discussion, high level networking and partnering, unique formats and a vetted, high-calibre audience, we bring together the people that matter to the future of healthcare and life science funding, finance, investment and deal making.

Biotech and Money Ltd.

Category: Content
Type: Blog Article

Generated 1 week ago

Biotech and Money Ltd.

Category: Content
Type: Blog Article

Generated 2 weeks ago

New blog articles detected

  • How Medtech Companies attract investment?

    What are the key factors for medtechs to attract investment?

  • 40+ Must Know Life Science Investors

    Who are some of the leading international investors most active this side of the Atlantic?  This ebook is a summary of over 40 of the life science industry’s most notable and active venture capital, corporate venture, strategic investors and PE / crossovers. The geography of this list is primarily UK and EU, but with several key US firms also listed. They represent a combined assets u...

  • What was the Biotech and Money Inv€$tival Showcase

    We were delighted to partner with the global investment bank Jefferies to launch the Biotech and Money Inv€$tival Showcase, co-located with the Jefferies 2016 London Healthcare Conference.

  • What is Medtech?

    Medtech is a very broad sector – it covers any technology that can be used in a care setting, which covers disposables, capital equipment and surgical procedure innovations, through to implant technology, biomaterials and connected health IT. Medtech accounts for all devices with which a patient can be diagnosed or treated: in diagnostics, a medical device is typically used in or on th...

  • How to make your IP investable

    At the core of any biotech company is an innovative piece of science which is believed will lead to new and beneficial healthcare products. The company’s Directors and advisors use their scientific insight and business acumen to push these new healthcare products along the road towards market.

  • Announcing the Launch of Biotech and Money's Healthcare Investor Insight Survey 2017

    Biotech and Money is proud to announce the launch of our inaugural Healthcare Investor Insight Survey and Report. The results and highlights of the report will be shared at the Biotech and Money London conference on 7-8 February, where you will also be able to acquire a copy.

  • How to make your IP investable

    This is the second in a series of four articles which aim to provide tips for creating and maintaining a patent portfolio that genuinely provides a biotech company with the hoped for IP position and makes it an attractive choice for investors. The first article focused on building a robust and investable patent portfolio.

  • 35+ Innovative Life Science Companies you'll want to meet in 2017

    Who are the innovative biotech and medtech companies presenting at Biotech and Money / Medtech and Money London 2017?

  • Of Mice and Men: Kymab scurries up the biologics ladder

    Using the pioneering Kymouse human antibody expression platform, Kymab are paving the way to a new era of antibody-based medicine. Already boasting two antibodies on their way to the clinic, Kymab’s investors are drawn to the platform’s breadth and potential, as 2020 promises to see a further four antibodies undergoing clinical trials. With distinguished investors such as the Wellcome ...

  • The role of SFOs in the Healthcare Sector

    Our ongoing mission at Biotech and Money is to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. One of the key ways we do that is by talking to and, more importantly, listening to our community. A topic that seemed to we’ve found to be of almost universal interest to companies of all sizes in...

Biotech and Money Ltd.

Category: Content
Type: Blog Article

Generated 4 months ago

New blog articles detected

  • Top 4 Tips You Need To Prepare For A Biotech IPO

    Biotech companies have fared well recently in the IPO market in both the US and the UK. New legislation in the US has eased access to public markets and the AIM market in London continues to be attractive for emerging biotech companies.

  • Further additions to the lineup of presenters at the Inv€$tival Showcase

    We’re delighted to announce further additions to the lineup of presenters at the Inv€$tival Showcase in partnership with Jefferies LLC on November 18 at the Hilton Waldorf in London. Joining the showcase are a selection of international public and private life science corporates in:

Biotech and Money Ltd.

Category: Content
Type: Blog Article

Generated 5 months ago

New blog articles detected

  • Exclusive sneak peak for the 3rd annual Biotech and Money London

    You'll be blown away by what we've got planned for our next flagship congress. Full details will be coming shortly, but for now we can offer you exclusive sneak peak at our plans for the 3rd annual Biotech and Money London, taking place on February 7-8, 2017.

  • Some highlights from Biotech and Money's recent MedTech Webinar

    On September 15th we spoke exclusively to a panel of MedTech CEOs and investors in the sector for the latest in our webinar series, discussing the new funding models for MedTechs and key strategies for accessing capital during the current slowdown in earlier stage investment.

  • 9 things we learned from F2G CEO Ian Nicolson

    Ian has over 25 years of international experience in management and transactions within the life sciences sector. In addition to his role at F2G, he is currently an Operating Partner of London-based Advent Life Sciences LLP. He has worked extensively in licensing, M&A and market development in the UK, Europe and the US and holds a BSc (Hons.) from University College London and an MBA f...

  • Biotech and Money interviews Mironid

    Comprising a team with expertise in both development and commercialisation, Mironid are hoping to follow-up their recent £4.3 million series A financing with enhanced focus on R&D, exploration of potential future collaboration and the potential for series B investment in the not-too-distance future. Here are 9 things we learned when Biotech and Money spoke to Executive Chairman Dr Paul...

Biotech and Money Ltd.

Category: Content
Type: Blog Article

Generated 5 months ago

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in